Literature DB >> 14499696

RFP2, c13ORF1, and FAM10A4 are the most likely tumor suppressor gene candidates for B-cell chronic lymphocytic leukemia.

W J van Everdink1, A Baranova, C Lummen, T Tyazhelova, M W G Looman, D Ivanov, E Verlind, A Pestova, H Faber, A Y van der Veen, N Yankovsky, E Vellenga, C H C M Buys.   

Abstract

Occurrence of 13q14 deletions between D13S273 and D13S25 in B-cell chronic lymphocytic leukemia (B-CLL) suggests that the region contains a tumor suppressor gene. We constructed a PAC/cosmid contig largely corresponding to a 380-kb 13q14 YAC insert that we found deleted in a high proportion of B-CLL patients. We found seven genes by exon trapping, cDNA screening and analysis/cDNA extension of known expressed sequence tags. One appeared to originate from another region of 13q. Recent publications have focused on two of the genes that most likely do not have a tumor suppressor role. This study evaluates the remaining four genes in the region by mutation scanning and theoretical analysis of putative encoded products. No mutations suggestive of a pathogenic effect were found. The 13q14 deletions may be a consequence of an inherent instability of the region, an idea supported by our finding of a considerable proportion of AluY repeats. Deletion of putative enhancer sequences and/or genes in the region may result in an inactivation of tumor suppression by a haploinsufficiency mechanism. We conclude that RFP2, c13ORF1, and a chromosome 13-specific ST13-like gene, FAM10A4, are the most likely candidates for such a type of B-CLL TSG.

Entities:  

Mesh:

Year:  2003        PMID: 14499696     DOI: 10.1016/s0165-4608(03)00126-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  Clld7, a candidate tumor suppressor on chromosome 13q14, regulates pathways of DNA damage/repair and apoptosis.

Authors:  Xiaobo Zhou; Karl Münger
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region.

Authors:  Aybike Birerdinc; Elizabeth Nohelty; Andrey Marakhonov; Ganiraju Manyam; Ivan Panov; Stephanie Coon; Eugene Nikitin; Mikhail Skoblov; Vikas Chandhoke; Ancha Baranova
Journal:  Tumour Biol       Date:  2009-12-18

3.  Human RFP2 gene promoter: unique structure and unusual strength.

Authors:  Mikhail Skoblov; Konstantin Shakhbazov; Dmitry Oshchepkov; Dmitry Ivanov; Anna Guskova; Dmitry Ivanov; Petr Rubtsov; Vladimir Prasolov; Nick Yankovsky; Ancha Baranova
Journal:  Biochem Biophys Res Commun       Date:  2006-02-17       Impact factor: 3.575

4.  An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.

Authors:  Wei Xiong; Xiaosong Wu; Sarah Starnes; Sarah K Johnson; Jeff Haessler; Siqing Wang; Lijuan Chen; Bart Barlogie; John D Shaughnessy; Fenghuang Zhan
Journal:  Blood       Date:  2008-03-12       Impact factor: 22.113

5.  Evaluation of 13q14 status in multiple myeloma by digital single nucleotide polymorphism technology.

Authors:  Katy Hanlon; Lorna W Harries; Sian Ellard; Claudius E Rudin
Journal:  J Mol Diagn       Date:  2009-07-30       Impact factor: 5.568

6.  TRIM13 is a negative regulator of MDA5-mediated type I interferon production.

Authors:  Kavitha Narayan; Lisa Waggoner; Serena T Pham; Gabriel L Hendricks; Stephen N Waggoner; Joseph Conlon; Jennifer P Wang; Katherine A Fitzgerald; Joonsoo Kang
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

7.  TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.

Authors:  Moshe E Gatt; Kohichi Takada; Mala Mani; Mikael Lerner; Marjorie Pick; Teru Hideshima; Daniel E Carrasco; Alexei Protopopov; Elena Ivanova; Olle Sangfelt; Dan Grandér; Bart Barlogie; John D Shaughnessy; Kenneth C Anderson; Daniel R Carrasco
Journal:  Br J Haematol       Date:  2013-05-07       Impact factor: 6.998

8.  ARLTS1 and prostate cancer risk--analysis of expression and regulation.

Authors:  Sanna Siltanen; Daniel Fischer; Tommi Rantapero; Virpi Laitinen; John Patrick Mpindi; Olli Kallioniemi; Tiina Wahlfors; Johanna Schleutker
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.